Lawsuits Allege Ozempic Caused Gastroparesis; Do You Have A Claim?

New York, NY As the demand for Ozempic and other semaglutide weight-loss drugs increases, more serious side effects such as stomach paralysis are being reported to medical professionals, the FDA, and attorneys.

Ozempic was not initially designed to be a weight-loss medication. When it was approved by the FDA in 2017, it was approved to help type-2 diabetics control their blood sugar and A1c levels. To this day, Ozempic is not FDA-approved for weight loss. However, the weight loss properties of semaglutide – the generic name for Ozempic – were quickly realized, and doctors began prescribing it “off-label” for weight loss. Further, other drugs, such as Wegovy, which is simply a higher dosage of semaglutide, would later obtain FDA approval for weight loss.



But as much as Ozempic has been in the news for its weight-loss properties, it has also been associated with potentially dangerous side effects, such as the above-mentioned stomach paralysis – or gastroparesis. Many of the lawsuits that have been filed against semaglutide drugs like Ozempic allege that the drug caused gastroparesis. 

Ozempic Lawsuit –Do I Qualify?

If you were prescribed Ozempic, Wegovy, or even pill form semiglutades such as Mounjaro and Zepbound for treatment of your diabetes or for long-term weight management and you have been diagnosed with gastroparesis you may have a claim.    
Symptoms that have been potentially connected to semaglutide use include:  

•           Gastroparesis
•           Stomach paralysis
•           Gastric obstruction
•           Pancreatic Cancer
•           Vomiting for 2+ Weeks

Some Ozempic users have needed surgeries for intestinal blocking but it is not yet known if those blockages are related to these products. 

The Ozempic lawsuits that have been filed allege that the Ozempic failed to warn about all of these risks. The main injury claimed across these lawsuits is gastroparesis, or a paralyzed stomach. Extensive vomiting is also commonly alleged to be associated with semaglutide use. However, those who have had lap band surgery, gastric sleeve surgery, or intestinal surgeries will not qualify.  Additionally, lawyers are not taking Ozempic cases for individuals who are undergoing cancer treatment, whether it is chemotherapy or radiation. 

Ozempic MDL

The U.S. Judicial Panel on Multidistrict Litigation (MDL) ordered in February 2024 that all current Ozempic lawsuits in federal court be centralized in the Eastern District of Pennsylvania and before the Honorable Gene E. K. Pratter. MDLs are similar to a class action, except that MDLs resolve each claim individually yet still allow judicial rulings and the discovery process to be streamlined. Class actions combine all claims into a single case resolved together.

Some lawyers attorneys at the forefront of Ozempic litigation anticipate at least 10,000 cases in the MDL. This is because semaglutides are very popular. Thus, it is anticipated that cases will continue to trend upward.